<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01852630</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS- SBP-01</org_study_id>
    <nct_id>NCT01852630</nct_id>
  </id_info>
  <brief_title>Imipenem Versus Cefepime in Spontaneous Bacterial Peritonitis and to Evaluate the Risk Factors for Treatment Failure</brief_title>
  <official_title>A Randomized, Comparative Open Label Study of Imipenem Versus Cefepime in Spontaneous Bacterial Peritonitis and to Evaluate the Risk Factors for Treatment Failure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. All consecutive patients with Cirrhosis and ascites admitted to ILBS (Institute of Liver
           &amp; Biliary Sciences) will be evaluated for the presence of SBP (Spontaneous Bacterial
           Peritonitis) by ascitic fluid examination at admission.

        2. SBP (Spontaneous Bacterial Peritonitis) will be diagnosed in the presence of absolute
           neutrophil count (ANC &gt;250/mm3) with/without positive ascitic fluid culture and Patients
           with SBP (Spontaneous Bacterial Peritonitis) included in the study will be randomized to
           receive cefepime or imipenem.

        3. However, other SBP (Spontaneous Bacterial Peritonitis) patients not included for
           randomization will be given empirical therapy with 3rd generation cephalosporin
           (ceftriaxone).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Baseline evaluation:

      Baseline clinical, laboratory and disease severity parameters will be evaluated for each
      study patient.

        1. Etiology of cirrhosis.

        2. Severity of liver disease. CTP (Child-Turcotte-Pugh) score MELD (Model for End-stage
           Liver Disease) score MELD (Model for End-stage Liver Disease)-Na score IMSAA score

        3. Decompensations/complications of CLD (Chronic Liver Disease) UGI bleed, Hepatic
           encephalopathy, AKI (Acute Kidney Injury) etc.

        4. Laboratory investigations:

      Serum electrolytes Liver function tests Kidney function tests Pro calcitonin USG/CT abdomen
      Complete blood counts Coagulation parameters Ascitic fluid analysis- TLC, DLC, Protein,
      sugar, culture, SAAG. Chest X ray PA view HBsAg and Anti-HCV and other etiological workup as
      available.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome of the study is the Response to treatment in each intervention group. Response is defined as 25% reduction in ANC (Absolute Neutrophil Count) from baseline.</measure>
    <time_frame>2 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>15 days,1 month and 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">175</enrollment>
  <condition>Spontaneous Bacterial Peritonitis</condition>
  <arm_group>
    <arm_group_label>cefepime + Albumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cefepime 1g iv 8 hourly + Albumin will be given for 2 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imipenem + Albumin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Imipenem 1g iv 8 hourly + Albumin will be given for 2 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cefepime + Albumin</intervention_name>
    <description>cefepime + Albumin will be given for 2 days</description>
    <arm_group_label>Imipenem + Albumin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipenem + Albumin</intervention_name>
    <description>Imipenem + Albumin will be given for 2 days.</description>
    <arm_group_label>cefepime + Albumin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Cirrhotic Patients with SBP (Spontaneous Bacterial Peritonitis) having any of the
        following risk factors would be considered as 'Difficult to Treat SBP' and would be
        included -

          1. Nosocomial SBP: occurence of SBP (Spontaneous Bacterial Peritonitis) after 48 hours of
             hospital admission, or

          2. Prior ascitic fluid infection with 3rd generation cephalosporin resistant organism, or

          3. No response to treatment with 3rd generation cephalosporins after 48 hours.

        Exclusion Criteria:

          1. Age less than 18 years.

          2. Cirrhotics with SBP (Spontaneous Bacterial Peritonitis) managed as outpatients.

          3. Post liver transplant, HIV patients.

          4. Patients on systemic chemotherapy, immunosuppressant drugs.

          5. Growth of bacteria resistant to intervention drugs in ascitic fluid culture.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Ankur Jindal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Liver &amp; Biliary Sciences (ILBS)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Liver &amp; Biliary Sciences (ILBS)</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2012</study_first_submitted>
  <study_first_submitted_qc>May 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2013</study_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peritonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>Cefepime</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

